ABEO
Abeona TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade B from latest DB weights. Momentum 70.0 / Value 41.1
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.8.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
70
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $21.75
Why
Momentum70 · Δ7d +1.8
Value41 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
70
52% active weight
Current posture
7d trendImproving
Δ7d
+1.8
Δ21d
-8.2
Value
41
48% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 70.0 / Value 41.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$320.88M
Beta
1.17
Shares Out
54.19M
P/E (TTM)
4.7
P/S (TTM)
707.20
P/FCF (TTM) · Derived
-3.94
Rev YoY
-100.0%
EPS YoY
+84.9%
Gross Margin
-122.0%
Op Margin
+17289.3%
Net Debt
-$78.76M
Current Ratio
9.74
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology